Ensartinib is approved by the USFDA for ALK-positive locally advanced or metastatic non-small cell lung cancer
On December 18, 2024, the Food and Drug Administration sanctioned ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small c..
Durvalumab is approved by the USFDA for limited-stage small cell lung cancer
On December 4, 2024, the Food and Drug Administration sanctioned durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose condition remains stable after concurrent platinum-b..
Zenocutuzumab-zbco is approved by the USFDA for non-small cell lung cancer and pancreatic adenocarcinoma
On December 4, 2024, the Food and Drug Administration granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus N.V.) for use in adults with specific conditions. Patients with advanced, unresectable, or meta..
Neoadjuvant/adjuvant nivolumab for resectable non-small cell lung cancer
On October 3, 2024, the Food and Drug Administration sanctioned nivolumab (Opdivo, Bristol Myers Squibb Company) in conjunction with platinum-doublet chemotherapy as neoadjuvant therapy, succeeded by single-agent nivolum..
Osimertinib is approved by the USFDA for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy
On September 25, 2024, the Food and Drug Administration sanctioned osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC)..
Amivantamab-vmjw with carboplatin and pemetrexed is approved by the USFDA for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations
On September 19, 2024, the Food and Drug Administration sanctioned amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in conjunction with carboplatin and pemetrexed for adult patients diagnosed with locally advanced or metastatic..
Atezolizumab and hyaluronidase-tqjs is approved by FDA for subcutaneous injection
On September 12, 2024, the Food and Drug Administration sanctioned atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) for subcutaneous administration for all adult indications corresponding to the intravenous..
LungVax: Lung cancer vaccine
Lung cancer vaccine The 'LungVax' vaccine, developed by researchers from the University of Oxford, the Francis Crick Institute, and University College London, employs technology akin to that of the very effective Oxford..
World-first lung cancer vaccine trials started in seven countries
August 2024: Medical professionals have initiated clinical trials for the first-ever mRNA lung cancer vaccine, which has been praised by specialists for its revolutionary ability to potentially rescue numerous lives. Lung cance..
Lazertinib with amivantamab-vmjw is approved by the USFDA for non-small lung cancer
August 2024: The Food and Drug Administration (FDA) has granted approval for the use of lazertinib (Lazcluze, Janssen Biotech, Inc.) in combination with amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) as the initial treatment ..